Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.
Phase 1
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000009881
- Lead Sponsor
- Sapporo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pregnancy or lactation 2)Patients with the intention of pregnancy. 3)Patients have uncontrollable severe infectional diseases. 4)severe diarrhea. 5)Patients who are treated with steroid or immunotherapy during clinical trial. 6)Patients have uncontrollable multiple cancer. 7)Patients who have non-recovered injury. 8)Patients who have ileus and interstitial lung disiease. 9)Patients whom doctors define as inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method